Beaumont Hospital's department of Urology is conducting a clinical research study for men who have the diagnosis of chronic prostatitis(CP) or chronic pelvic pain syndrome (CPPS). It is a phase II, open-label, 16 week drug (CC-10004, also known as apremilast) study.

Due to the inflammatory nature of CP/CPPS, most prior therapies have focused on targeting the inflammation. CC-10004, in several studies, has shown to be an inhibitor of inflammatory mediators and may decrease the pain experienced from CP/CPPS.

Men, 18 years and older with at least 3 months of symptoms of CP/CPPS (pain in the pelvic area, penis, scrotum or perineum) who are refractory to other therapies (e.g. NSAIDS) may be eligible to participate.

For more information, contact Cindy Turzewski, RN at 248-551-9446 or at Cynthia.Turzewski@beaumont.edu

.........................................................................................
This information is forwarded to you by the Prostatitis Foundation. We do not provide medical advice. We distribute literature and information relevant to prostatitis. While we encourage all research we do not endorse any doctor, medicine or treatment protocol. Consult with your own physician.

© The Prostatitis Foundation
.........................................................................................